


Engineering Modular Viral Scaffolds for Targeted Bacterial Population Editing

Graphical Abstract



Authors

Hiroki Ando, Sebastien Lemire,
Diana P. Pires, Timothy K. Lu

Correspondence

timlu@mit.edu

In Brief

The establishment of a bacteriophage genome-engineering platform and the creation of synthetic phages with tunable host ranges open the door for building synthetic phage cocktails based on common viral scaffolds. This approach was used to enact efficient killing of targeted bacteria and edit multi-species communities and thus enables new technologies for treating infectious diseases and modulating microbial consortia.

Highlights

- A generalizable and efficient strategy for phage genome engineering was established
- Synthetic phages with tunable host ranges were created
- Engineered phages enacted efficient killing of their new target bacteria
- Phage cocktails with engineered host ranges edited mixed bacterial populations



Engineering Modular Viral Scaffolds for Targeted Bacterial Population Editing

Hiroki Ando,¹ Sebastien Lemire,¹ Diana P. Pires,^{1,2} and Timothy K. Lu^{1,*}

¹Department of Electrical Engineering and Computer Science and Department of Biological Engineering, Synthetic Biology Center, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA

²Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal

*Correspondence: timlu@mit.edu

<http://dx.doi.org/10.1016/j.cels.2015.08.013>

SUMMARY

Bacteria are central to human health and disease, but existing tools to edit microbial consortia are limited. For example, broad-spectrum antibiotics are unable to precisely manipulate bacterial communities. Bacteriophages can provide highly specific targeting of bacteria, but assembling well-defined phage cocktails solely with natural phages can be a time-, labor- and cost-intensive process. Here, we present a synthetic biology strategy to modulate phage host ranges by engineering phage genomes in *Saccharomyces cerevisiae*. We used this technology to redirect *Escherichia coli* phage scaffolds to target pathogenic *Yersinia* and *Klebsiella* bacteria, and conversely, *Klebsiella* phage scaffolds to target *E. coli* by modular swapping of phage tail components. The synthetic phages achieved efficient killing of their new target bacteria and were used to selectively remove bacteria from multi-species bacterial communities with cocktails based on common viral scaffolds. We envision this approach accelerating phage biology studies and enabling new technologies for bacterial population editing.

INTRODUCTION

Bacteriophages (phages) are natural biological nanomachines that have evolved to infect host bacteria with exquisite specificity and efficacy. Phages constitute the most abundant type of biological particles on Earth (Hendrix, 2003) and reproduce at the expense of their host bacteria. Thus, phages have been explored as a means of controlling pathogenic bacteria (d'Herelle, 1931), but a poor understanding of the molecular relationships between bacteria and their phages can lead to highly variable treatment outcomes (Brüssow, 2012; Lu and Koeris, 2011). With the rise of drug-resistant bacterial infections and the sharp decline in antibiotic discovery and development (Fischbach and Walsh, 2009), phage therapy is regaining attention after years of declining interest (Carlton, 1999; Lu and Collins, 2007, 2009). Furthermore, despite the important role that microbial populations play in regulating human health and disease (Grice and Segre, 2012), strategies for precisely manipulating complex mi-

crobial communities are lacking. With their ability to kill or deliver DNA into specific bacteria, phages constitute a promising platform for editing microbial populations (Bikard et al., 2014; Citorik et al., 2014). However, the limited host range of most naturally isolated phages means that phage cocktails are often needed to address real-world applications (Sulakvelidze et al., 2001), but the high diversity of natural phages poses a challenge for the engineering, manufacturing, and regulatory approval of phage products. Thus, enhancing the range of targetable bacteria by adding natural phages to cocktails is counterbalanced with the challenge of producing and testing well-defined multi-component mixtures for regulatory approval.

Creating phage-based therapeutics and diagnostics is also limited by the difficulty of engineering phages. Lytic phage DNA is often too large for in vitro manipulation and does not reside for very long inside of bacteria, making it difficult to modify phage genomes during their reproductive cycle. Phage genome engineering is classically carried out with allele replacement methods, whereby a piece of the phage genome is cloned and manipulated in bacteria, which is then infected with the phage, leading to homologous recombination of the modified DNA segment into the phage genome. This process is inefficient, because many phages degrade resident DNA upon entry, and time consuming, due to the need to screen for recombinant phages but the lack of phage selectable markers. Recently, CRISPR-Cas systems have been used for counter-selection against phage T7 and the heavily modified genomes of a few members of the T-even family (Kiro et al., 2014; Martel and Moineau, 2014; Yang et al., 2014). We have used the *Streptococcus pyogenes* CRISPR-Cas9 system to select for mutants in phage T7 but with variable efficiencies (data not shown). Furthermore, large stretches of phage DNA can encode products toxic to bacteria, thus preventing their manipulation within bacterial hosts. Existing approaches are also limited in their ability to simultaneously engineer multiple non-contiguous loci in phage genomes. Here, we demonstrate a high-throughput phage-engineering platform that leverages the tools of synthetic biology to overcome these challenges and use this platform to engineer phages with tunable host ranges for microbial population editing.

RESULTS

Yeast Platform for Bacteriophage Genome Engineering

We used an efficient yeast-based platform (Jaschke et al., 2012; Lu et al., 2013) to create phages with novel host ranges based on




Figure 1. Yeast Platform for Phage Engineering

(A) Schematic illustrating the workflow to capture and reboot phages using our yeast platform. An entire phage genome or all PCR products spanning an entire phage genome are transformed into yeast cells, along with a linearized yeast replicon fragment from the yeast artificial chromosome, pRS415. In yeast, the phage genome is assembled and captured in the YAC by gap repair cloning. The resultant YAC-phage DNA is extracted and transformed into host bacteria. Active phages are produced from the YAC-phage DNA and generate plaques on a lawn of host bacteria.

(B) High-titer phage lysates ($>10^9$ PFU/ml) were spotted onto *E. coli* 10G lawns, which were sensitive only to T7 and T3 phages.

(C) Rebooting T7 and T3 phages from purified phage genomes (10 ng) after electroporation into 10G, recovery in LB, chloroform sterilization, and plating with *E. coli* BL21.

(D) All tested phage genomes (10–200 ng), including non-*E. coli* phages, could be rebooted by electroporation into *E. coli* 10G cells and plating supernatants with host bacteria. Host bacteria used to plaque rebooted phage genomes were IJ1668 K-12 hybrid; K1 capsule for K1E, K1F, and K1-5 phages, IJ612 *Salmonella typhimurium* LT2 for SP6 phage, *Pseudomonas aeruginosa* PAO1 for LUZ19 phage, *Pseudomonas putida* C1S for gh-1 phage, and *Klebsiella* sp. 390 for K11 phage.

(E) An example of capturing and rebooting a phage through the yeast platform. An excised YAC pRS415 amplicon and the T7 genome were co-transformed in yeast cells. The T7 genome was captured in the YAC by gap repair cloning in yeast. Progeny phages were produced from YAC-T7 DNA via *E. coli* 10G and generated plaques on *E. coli* BL21.

common viral scaffolds. Inspired by gap repair cloning in yeast and the work of Gibson et al. (2008), we captured phage genomes into *Saccharomyces cerevisiae*, thus enabling facile genetic manipulation of modified genomes that can be subsequently reactivated or “rebooted” into functional phages after transformation of genomic DNA into bacteria (Figure 1A). First, the entirety of the viral genome to be assembled in yeast is amplified by PCR so that each adjacent fragment has homology over ≥ 30 bp. The first and last fragments of the phage genome are amplified with primers that carry “arms” that have homology with a yeast artificial chromosome (YAC) fragment, which may be obtained by PCR or any other suitable method. Upon transformation of all viral genome fragments and the YAC into yeast, gap repair joins each fragment to the adjacent one templated by the homology regions at the end of each fragment, yielding a full phage genome cloned into a replicative yeast plasmid. Yeast transformants are then enzymatically disrupted to extract the

YAC-phage DNA, which is transformed into bacterial host cells that can restart the viral life cycle. Plaques, if obtained, are then picked, amplified, and sequenced to verify proper introduction of the desired mutations. If no plaques are obtained, it is still possible to amplify parts of the YAC-phage genome from the yeast clones to verify proper DNA assembly, to eliminate the possibility of unwanted mutations, and to help determine potential reasons for the failure of the synthetic phage genome to produce viable offspring.

We confirmed that purified phage DNA from various phages could be transformed into bacterial hosts to generate functional phages. We targeted phages from the T7-family because their life cycle is largely host independent (Qimron et al., 2010) and there is a relatively large number of family members for which genomic sequences are publicly available. These include coliphages T7 (40 kbp), T3 (38 kbp), K1E (K1-capsule-specific, 45 kbp), K1F (K1-capsule-specific, 40 kbp), K1-5 (K1- or K5-capsule-specific, 44




Figure 2. Creation of Synthetic Phages with Engineered Host Range

(A) We prepared multiple PCR fragments encoding the wild-type T7 phage genome (T7_{WT}) (PCR fragments 1–4; 10.0, 10.0, 10.0, and 10.1 kbp, respectively), T7 phage with the entire T3 phage tail fiber (T7_{T3(gp17)}) (PCR fragments 1–3 and 5–7; 10.0, 10.0, 10.0, 4.7, 1.7, and 3.7 kbp, respectively), and T7 phage with a hybrid T7-T3 tail fiber (T7_{T3(C-gp17)}) (PCR fragments 1–3, 8, 9, and 7; 10.0, 10.0, 10.0, 5.2, 1.3, and 3.7 kbp, respectively). All fragments were co-transformed and assembled in yeast along with YAC DNA (3.0 kbp).

(B) Phage A with its primary host determinant, gene *a*, infects bacteria A, but cannot infect bacteria B. Phage B with its primary host determinant, gene *b*, infects bacteria B, but cannot infect bacteria A. We hypothesized that swapping these host determinants between phages would switch their respective host ranges.

(C) Creation of synthetic T7 phage with phage 13a tail fiber (encoded by gene 17). We synthesized 13a's gene 17 and assembled it with the rest of the T7 genome via overlapping PCR products in yeast (PCR fragments 1–6 and YAC amplicon; 10.0, 10.0, 10.0, 4.8, 1.7, 3.7, and 3.0 kbp, respectively). The YAC-phage DNA was extracted and used for transformation.

kbp), *Salmonella* phage SP6 (44 kbp), *Pseudomonas* phages LUZ19 (44 kbp), gh-1 (37 kbp), and *Klebsiella* phage K11 (41 kbp). We used *E. coli* 10G (10G) cells (Durfee et al., 2008) as a one-time phage propagation host. Except for T7 and T3, all phages used in this study (K1E, K1F, K1-5, SP6, LUZ19, gh-1, and K11) cannot infect 10G (Figure 1B). Each purified phage genome was electroporated into 10G directly. After incubation and chloroform treatment, supernatants were mixed with overnight cultures of each natural host bacteria for each phage in soft agar, poured onto agar plates, and scored for plaque formation (Figures 1C and D). All the phages tested could be rebooted from purified DNA into functional phages through one-step propagation in 10G, even if their natural target species was not *E. coli* (Figure 1D; Table S1).

Rebooting Bacteriophages from PCR Products via the Yeast Platform

To determine whether phage genomes assembled in yeast can be used to create viable phages, we first captured and rebooted T7 (Figure 1E), T3, and LUZ19 phages. We used PCR to amplify the YAC pRS415 and add arms homologous to the ends of the phage genomes. We co-transformed the YAC amplicons with phage genomic DNA into yeast. Confirmed YAC-phage DNA was extracted from yeast and transformed into *E. coli* 10G. These cells were then chloroform treated, and the lysates were assessed for plaque-forming units (PFUs) on the natural bacterial hosts of the phages (see Figure 1E for capturing and rebooting T7). All three phage genomes yielded yeast clones that could be rebooted to viable phages using this strategy.

Next, we successfully captured and rebooted eight different phages that target *E. coli*, *Salmonella*, *Pseudomonas*, and *Klebsiella* (T7, T3, K1E, K1F, K1-5, SP6, gh-1, and K11) by assembling overlapping 3.8- to 12-kbp-long PCR products spanning

the phage genomes with the linearized YAC in yeast (Figure 2A, upper panel illustrates this process with T7 as an example; data not shown for the others). These data demonstrate the efficient assembly and instantiation of functional recombinant phages via our yeast-engineering platform, which can potentially create any desired genotype in one step from PCR products.

Swapping Tail Fibers Enables Modulation of Phage Host Range

We explored the utility of our phage-engineering platform by engineering the host range of phages. We first selected two model phages, T7 and T3, which are well-known obligate lytic phages that propagate on *E. coli* B (Demerec and Fano, 1945). T7 and T3 have linear genomes that share high homology with each other, in which the primary host determinant is the product of gene 17 (gp17), the tail fiber (Dunn and Studier, 1983; Pajunen et al., 2002). Alterations in the gp17 sequence have been linked to the recognition of different host receptors and shifting host ranges (Molineux, 2006). Thus, we hypothesized that exchanging gene 17 or fragments of gene 17 between T7, T3, and their relatives could be used to tune their host specificities (Figure 2B). This is supported by previous data on naturally occurring hybrids between T7 and T3, whose host range was mostly dictated by which gp17 they harbored (Lin et al., 2012).

We examined the host range of T7 and T3 phage on diverse bacterial panels that were differentially targeted by the two phages. T3 is described as incapable of targeting many common lab *E. coli* K-12 strains (Molineux, 2006), so we performed plaque formation assays with four K-12 strains and a B strain (BL21) as a control. As shown in Figure S1A, T7 plaqued efficiently on all strains, while T3 did not produce plaques on BW25113 and MG1655 at a detectable frequency (Figure 3). T3 exhibited ~3–4 orders-of-magnitude reductions in adsorption efficiency




Figure 3. EOP of Natural, Reconstructed Wild-Type, and Synthetic Phages

EOP was determined with respect to a reference bacterium. *Klebsiella* sp. 390 was used as a reference for T7_{K11(gp11-12-17)}, K11, and K11_{WT}. *Y. ptb* IP2666 was used for T3_{R(gp17)}. For other phages, BL21 was used as the reference host. EOP data were log₁₀ transformed and are presented as the mean of three independent experiments. Error bars represent SD. The "0" symbol indicates an EOP = 1, which marks the reference strain used for the EOP calculations within each phage. An asterisk indicates that the EOP was below the detection limit (EOP < 10⁻⁸). Strain abbreviations are B, *E. coli* BL21; G, *E. coli* 10G; D, *E. coli* DH5 α ; W, *E. coli* BW25113; M, *E. coli* MG1655; 4, *E. coli* ECOR4; 13, *E. coli* ECOR13; 16, *E. coli* ECOR16; K, *Klebsiella* sp. 390; I, *Y. ptb* IP2666; Y, *Y. ptb* YPIII; N, *E. coli* Nissle 1917.

on BW25113 and MG1655 compared with the permissive BL21 strain (Figure S1B). Thus, we can differentiate between T7 and T3 using BW25113 or MG1655.

The gp17 tail fibers of T7 and T3 can be split in two domains. The N-terminal 149 residues are thought to be necessary for the tail fiber to bind to the rest of the capsid, while the remaining C-terminal region forms a kinked shaft and harbors the recognition domain for host receptors at its tip (Steven et al., 1988). The N-terminal regions of T7 and T3 share 99% identity at the protein level, while the C termini exhibit 83% identity, with the last 104 amino acids (aa) of the T3 protein showing only 62% of identity to the corresponding 99 aa of the T7 protein. Therefore, we hypothesized that swapping the C-terminal domain between the two viruses would result in exchanging the host ranges. We constructed synthetic phages, based on either the T7 or T3 viral chassis, which carried engineered gene 17 alleles composed of fragments from the other phage. Specifically, we created six synthetic phages: T7 phage with the wild-type T7

tail fiber (T7_{WT}), T7 phage with the C-terminal 410 aa region of the T3 tail fiber (T7_{T3(C-gp17)}), T7 phage with the entire T3 tail fiber (T7_{T3(gp17)}), T3 phage with the wild-type T3 tail fiber (T3_{WT}), T3 phage with the C-terminal 405 aa region of the T7 tail fiber (T3_{T7(C-gp17)}), and T3 phage with the entire T7 tail fiber (T3_{T7(gp17)}). T7_{WT} and T7 phages are the same at the genetic level; however, T7_{WT} phage was created by capturing the T7 genome in yeast and then rebooting this phage genome in bacteria and served as a control for the faithfulness of the reconstruction process, whereas T7 was obtained from ATCC. The same applies to T3_{WT} and T3. Each phage was assembled in yeast via four or six PCR fragments and was rebooted via transformation into *E. coli* 10G (example schematics in Figure 2A). No unexpected mutations were found in the heterologous gp17 regions of the rebooted phages.

To examine the host specificities of our six engineered phages, we performed plaque formation assays on a range of *E. coli*, *Klebsiella*, and *Yersinia pseudotuberculosis* (*Y. ptb*)




Figure 4. Creation of Synthetic T3 Phage with *Yersinia* Phage R Tail Fiber

(A) We introduced mutations in T3 gene 17 by PCR to convert it into phage R gene 17 and assembled the resultant product with the rest of the T3 genome and YAC DNA in yeast (PCR products 1–6 and YAC amplicon; 10.0, 10.0, 10.0, 4.4, 0.2, 3.8, and 3.0 kbp, respectively). The YAC-phage DNA was extracted and used for transformation into *E. coli*.

(B) Plaque assay with T3_{WT} and T3_{R(gp17)} on *E. coli* BL21, *Y. ptb* IP2666, and *Y. ptb* YPIII shows that T3_{R(gp17)} can infect both *E. coli* and *Y. ptb*. 10-fold serial dilutions of phage lysates were spotted on bacterial lawns and incubated for 4 hr at 37°C for *E. coli* BL21 or 24 hr at 30°C for *Y. ptb* strains. These pictures were cut out from Figure S2. The bottom panels show images of individual plaques. NP, no plaque.

(C) Killing curves of *Y. ptb* IP2666 treated with T3_{R(gp17)}: $\sim 10^8$ CFU/ml bacteria and $\sim 10^7$ PFU/ml phage were used (MOI ~ 0.1). The data are presented as the mean of three independent experiments. Error bars represent SD. Small error bars are obscured by symbols. The detection limit was 2.0×10^3 CFU/ml.

strains (Figures 3 and S2). T3_{T7(C-gp17)} and T3_{T7(gp17)} plaqued on *E. coli* BW25113 and *E. coli* MG1655 at a similar EOP as T7 and T7_{WT}, while T3, T3_{WT}, T7_{T3(C-gp17)}, and T7_{T3(gp17)} had $>10^8$ -fold-reduced EOPs on these strains. In addition, T3, T7_{T3(C-gp17)}, and T7_{T3(gp17)} plaqued on *E. coli* ECOR16, while T7, T3_{T7(C-gp17)}, and T3_{T7(gp17)} did not. Furthermore, we also synthesized a codon-optimized version of the tail fiber of the T7-like coliphage 13a and created synthetic T7 phages containing the entire 13a tail fiber (T7_{13a(gp17)}) or the C-terminal region of the 13a tail fiber (T7_{13a(C-gp17)}) (Figure 2C; Table S2). Although T7 and T7_{WT} did not plaque on *E. coli* ECOR16, both T7_{13a(gp17)} and T7_{13a(C-gp17)} were able to do so efficiently (Figures 3 and S2). Thus, the C-terminal region of gp17 is a major host range determinant, and new host ranges can be conferred onto T7-like phage scaffolds by engineering tail fibers. Interestingly, T7_{13a(C-gp17)} efficiently infected *E. coli* BW25113 and MG1655, similar to T7 and T7_{WT}, but T7_{13a(gp17)} did not, which suggests that the N terminus of the phage 13a tail fiber can also alter infectivity of the virus, although the mechanism is still to be investigated (Figure 3). A second example of this phenomenon can be found between T7_{T3(C-gp17)} (Figures 3 and S2, lane 3) and T7_{T3(gp17)} (Figures 3 and S2, lane 4). While the former phage infected *Y. ptb* YPIII (albeit with a low EOP), the latter phage and wild-type T3 did not.

Coliphage T3 with a *Yersinia* Phage Tail Fiber Infects both *E. coli* and *Y. pseudotuberculosis*

We further demonstrated that gene swapping between phages can overcome species barriers by designing synthetic phage based on T7 or T3 scaffolds that can infect bacteria other than *E. coli*. We started with coliphage T3 and *Yersinia* phage R (38 kbp), since their gp17's share 99.5% identity at the protein level

and differ by only three nucleotides in gene 17, suggesting these could be responsible for their divergent host ranges. We introduced these three mutations in T3 gene 17 by PCR so that it would encode the same tail fiber as phage R (Figure 4A). While T3 did not plaque on *Y. ptb* strains IP2666 and YPIII, which are known hosts for phage R (Rashid et al., 2012), synthetic T3 phage with the R tail fiber (T3_{R(gp17)}) was able to infect *Y. ptb* IP2666 and YPIII (Figures 3 and S2). The adsorption efficiencies of T3_{WT} and T3_{R(gp17)} against *Y. ptb* IP2666 were found to be $0.01\% \pm 0.01\%$ and $90.05\% \pm 1.1\%$, respectively.

Interestingly, T3_{R(gp17)} maintained the capacity to infect *E. coli* BL21 (Figure 4B), demonstrating that the introduced mutations conferred a host range expansion, and not just a host range shift. In addition to plaque assays, we further characterized the ability of T3_{WT} versus T3_{R(gp17)} to kill *Y. ptb* IP2666 over time. After 1.5 hr of treatment, T3_{R(gp17)} killed 99.999% of IP2666, while T3 had no effect on the bacteria (Figure 4C; Table S3A).

Redirection of Host Range between Coliphage and *Klebsiella* Phage by Swapping Whole-Tail Components

We further overcame species barriers by engineering phages with lower similarity with one another. K11 is a *Klebsiella* phage that belongs to the T7-like family (Dietz et al., 1990). K11 shares gene synteny with T7, but homology between K11 and T7 genes is low, averaging only 59% among the genes that have homologs between the two viruses. For comparison, T7 and T3 share 72% identity at the genomic level between homologous genes. While T7 is a coliphage and does not infect *Klebsiella*, K11 infects *Klebsiella*, such as *Klebsiella* sp. 390, but not *E. coli* (Figures 3 and S2) (Bessler et al., 1973). Their respective host range determinants, gp17, are very different and do not share any homology outside of the N-terminal 150 amino acids, which is only 47% identical




Figure 5. Creation of Synthetic T7 Phage with *Klebsiella* Phage K11 Tail Components as well as K11 Phage with T7 Tail Components

(A) The tail complex of T7 phage is composed of two components: a tubular structure and tail fibers. The tubular structure consists of an upper dodecameric ring made of adaptor protein gp11 and a pyramidal hexameric complex of the nozzle protein gp12. The tail fiber protein gp17 interacts with the interface between gp11 and gp12 (Cuervo et al., 2013). Schematics illustrate the construction of synthetic hybrids between phages T7 and K11. Whole genomes were amplified as overlapping PCR amplicons. PCR fragments were co-transformed and assembled in yeast (PCR fragments 1–8 and YAC amplicon; 10.0, 10.0, 4.3, 3.0, 2.7, 4.8, 2.7, 3.7, and 3.0 kbp, respectively). YAC-phage genomes were extracted and used for trans-formation. We swapped K11 genes 11, 12, and 17 into T7 to create T7_{K11(gp11-12-17)} and T7 genes 11, 12, and 17 into K11 to create K11_{T7(gp11-12-17)}. (B) Plaqueing of T7_{K11(gp11-12-17)} and K11_{T7(gp11-12-17)} on *E. coli* BL21 and *Klebsiella* sp. 390. 10-fold serial dilutions of phage lysates were spotted on bacterial lawns and incubated for 4 hr at 37°C.

These pictures were cut from Figure S3. The bottom panels show images of individual plaques. NP, no plaque.

(C) Killing curves of *Klebsiella* sp. 390 treated with T7_{K11(gp11-12-17)}. $\sim 10^8$ CFU/ml bacteria and $\sim 10^7$ PFU/ml phage were used (MOI ~ 0.1). The data are presented as the mean of three independent experiments. Error bars represent SD. Small error bars are obscured by symbols. The detection limit was 2.0×10^3 CFU/ml.

between the two proteins. Specifically, the T7 gp17 encodes tail fibers, while the 322-aa-longer K11 gp17 directs the synthesis of a tail spike, an enzymatic host range determinant that actively breaks down the capsule of *Klebsiella* to allow the K11 phage to gain access to unknown secondary receptors located beneath the capsule (Bessler et al., 1973).

To create a T7 phage with a K11 tail fiber and a K11 phage with a T7 tail fiber, we first swapped the entire gene 17, but this yielded no viable phages. We then tried to construct composite tail fibers composed of gene 17 fragments from both phages hybridized at various points along the length of the gene, but this was also unsuccessful at generating functional synthetic phages. We speculated that one possible reason for these failures could be that the K11 genome cannot create productive phages within *E. coli* 10G. However, the natural K11 genome produced *Klebsiella*-infecting virions when it was rebooted via 10G cells (Figure 1D; Table S1).

Alternatively, the gene 17 product from K11 may require a function or factor that is absent from T7. Cuervo et al., (2013) reported that the tail of T7 phage, which assembles independently of the head, is assembled from a dodecamer of gp11 (the adaptor) and a hexamer of gp12 (the nozzle) (Figure 5A, upper), onto which six trimers of gp17 attach. T7's six tail fibers attach at the interface between the adaptor and nozzle, thus making contacts with both proteins. The adaptor ring is responsible for the attachment of the preformed tail to the prohead via interactions with the portal composed of 12 subunits of gp8. The homology between the gp8 of T7 and K11 (80% identity at the amino acid level) is much higher than the homology between the gp11 and gp12 proteins of T7 and K11 (60 and 61% identity, respectively), which led us to suspect that replacing all three tail genes of T7 with their K11 equivalents (gp11, gp12, and gp17) could be necessary to create

functional virions (Figure 5A, lower). Indeed, both T7 with K11 tail components (T7_{K11(gp11-12-17)}) and K11 with T7 tail components (K11_{T7(gp11-12-17)}) were successfully created and exhibited tail-dependent host ranges. Specifically, T7_{K11(gp11-12-17)} infected *Klebsiella* sp. 390 and did not target *E. coli*, while K11_{T7(gp11-12-17)} infected *E. coli* but did not plaque on *Klebsiella* (Figures 3, 5B, and S2). The yeast-based phage engineering platform enabled the facile construction of these phages via one-step genome construction even though gene 11 and 12 are physically separated from gene 17, a feat that would be difficult to achieve with other phage engineering methods. To further validate the ability of synthetic T7_{K11(gp11-12-17)} to target *Klebsiella*, we performed a time-course experiment that showed that T7_{K11(gp11-12-17)} killed 99.955% of *Klebsiella* sp. 390 after 1 hr of treatment (Figure 5C; Table S3B), but was about 100-fold less effective than K11_{WT} (Figures 5B and S3). Measured adsorption efficiencies of T7_{K11(gp11-12-17)} and K11_{WT} against *Klebsiella* sp. 390 were $98\% \pm 2\%$ and $92\% \pm 6\%$ after 10 min, respectively, suggesting that the reduced efficacy of T7_{K11(gp11-12-17)} is not due to an adsorption defect.

Synthetic Phage Cocktails Efficiently Remove Target Bacteria from Mixed Bacterial Populations

Our results show that common phage scaffolds can be retargeted against new bacteria hosts by engineering single or multiple tail components. This capability enables the construction of defined phage cocktails that only differ in their host-range determinants and can be used to edit the composition of microbial consortia and/or treat bacterial infections. To demonstrate microbial population editing using synthetic phages derived from T7 or T3 scaffolds but with differing host specificities, we designed experiments to remove specific bacteria from mixed




Figure 6. Microbial Population Editing Assay

A synthetic microbial community composed of *E. coli* Nissle 1917, *Klebsiella* sp. 390, and *Y. ptb* IP2666 was treated with various individual synthetic phages and a pairwise combination of phages. After adding $\sim 10^7$ PFU/ml of each phage, the resultant samples were incubated at 30°C with shaking for 1 hr. At each time point, bacteria were collected, washed in saline, serially diluted, and plated onto selective plates for viable cell counts after a 24-hr incubation at 30°C. The data are presented as the mean of three independent experiments, and the total numbers of cells (CFU/ml) are shown. The sizes of the pie charts reflect the total number of cells. Note that the chart does not allow the display of fractions smaller than $\sim 1\%$. The detailed data and the SD are shown in Table S4A. The detection limit was 2.0×10^3 CFU/ml.

populations containing *Klebsiella* sp. 390, *Y. ptb* IP2666, and the probiotic *E. coli* strain Nissle 1917. The amount of each bacterial member in this mixed population was quantified using their differing sensitivities to chemical antimicrobials (Figure S4). After a 1-hr treatment of the multi-species population with T7_{K11(gp11-12-17)} or T3_{R(gp17)}, >99.9% or >99% of their target bacteria, *Klebsiella* sp. 390 or *Y. ptb* IP2666, respectively, were removed with no detectable impact on the remaining bacterial species (Figure 6; Table S4A). Furthermore, a phage cocktail consisting of two phages with the same chassis but different host ranges, T7_{WT} and T7_{K11(gp11-12-17)}, resulted in >99.9% killing of *Klebsiella* sp. 390 and >99.9% killing of *Y. ptb* IP2666 after 1 hr, thus enriching for probiotic *E. coli* Nissle 1917 (Figure 6; Table S4A).

We performed similar assays with a phage cocktail consisting of two phages based on the T3 chassis (Figure S5). In this experiment, we used a mixed bacterial population containing the probiotic *E. coli* strain Nissle 1917, *E. coli* ECOR16 (sensitive to T3_{WT}), and *Y. ptb* IP2666 (sensitive to T3_{R(gp17)}). After a 1-hr treatment with a phage cocktail consisting of two phages with the same T3 chassis but different host ranges, T3_{WT} and T3_{R(gp17)}, >99.9% *E. coli* ECOR16 and >98% *Y. ptb* IP2666 were killed without affecting the remaining probiotic *E. coli* Nissle 1917 (Figure S6; Table S4B). These results demonstrate the high efficiency and selectivity of our engineered phages in microbial consortia and the potential of generating well-defined phage cocktails and combining them with probiotics.

DISCUSSION

In this study, we utilized an efficient, yet simple, yeast-based platform for phage engineering to modulate phage host ranges for several members of the T7 phage family. Traditional phage engineering strategies, such as in vitro manipulation, allele-exchange within bacterial hosts, and phage crossing via co-infec-

tion of bacteria (Beier et al., 1977; Garcia et al., 2003; Lin et al., 2011) have been used to modulate phage host range (Pouillot et al., 2010; Tétart et al., 1998; Trojet et al., 2011; Yoichi et al., 2005), but these strategies are inefficient and unable to achieve multiple genetic modifications in a single step. Screening for a desired mutation after classical crossing or recombination experiments can require PCR, restriction digestion, or plaque hybridization on hundreds of individual plaques, which are all costly and time-consuming methods. Conversely, our strategy rarely requires the screening of more than a few yeast clones, since we found that >25% of yeast clones contained properly assembled phage genomes (composed of up to 11 DNA fragments) that were bootable into functional phages after transformation into bacteria. Previously, a scheme for engineering phage T4 through electroporation of PCR products was devised (Pouillot et al., 2010), but it is based on a particular feature of the genetic regulation of T4 and cannot easily be applied to other phage families. Recently, the 5.4-kb filamentous coliphage ϕ X174 was assembled in yeast in order to stably store the genome and aid in phage refactoring (Jaschke et al., 2012). In this approach, the majority of the genome assembly was performed in vitro, and the YAC cloning was mostly used to store the resulting genome, whereas the majority of the genome engineering in our approach stems from the actual gap repair cloning process in yeast. In addition, the phages we have cloned using this method are in the 38–45 kbp range, and we have indications that they can also be used for much larger phage genomes (e.g., up to 100 kbp; data not shown). Leveraging yeast to modify phages enables the decoupling of phage genome engineering from phage fitness and viability, obviates the need for selective or screenable markers in phage genomes, reduces the risks of phage contamination during the engineering process, and permits facile one-step genetic manipulations. For example, the ability to simultaneously engineer multiple loci in a phage genome was crucial for constructing T7_{K11(gp11-12-17)} and K11_{T7(gp11-12-17)}.

However, a challenge of yeast-based phage engineering (which is shared by in vitro engineering strategies) is the need

to reboot modified phage genomes into functional phages. Here, we used high-efficiency DNA transformation to deliver phage DNA into bacterial hosts, but future work may be facilitated by in vitro transcription-translation systems capable of supporting functional phage synthesis (Shin et al., 2012). Another challenge for the approach outlined here is identifying the loci that can be manipulated to change phage host range. We anticipate that the systematic construction of phage mutants will enable more detailed mapping of host range determinants and potentially of their bacterial targets. Phages, such as T7, T3, or R, initiate contact with their hosts through their tail fibers encoded by gene 17 (Hu et al., 2013). On *E. coli* B strains, T3 recognizes the penultimate glucose residue of the lipopolysaccharide (LPS), while T7 binds to an undetermined site further inward in the LPS (Molineux, 2006). The exact receptor of phage R has not been determined but may be somewhere within the LPS of *Y. ptb*, since the related phage phiA1122 has been shown to plaque efficiently on strains of *E. coli* expressing the core LPS of *Yersinia* (Kiljunen et al., 2011). The actual receptor bound by *Klebsiella* phage K11 has not been formally documented but by analogy to phage T7, we assumed that its gene 17 bore its host-determinant activity. Interestingly, K11's gp17 is known to be a capsule depolymerase specific to the K11 capsule of *Klebsiella* (Bessler et al., 1973) and we suspect that it is a tail spike because known *Podoviridae* that bind to and degrade capsules or smooth O-antigens (e.g., K1F, SP6, P22, K1-5, and K1E) display tail spikes instead of fibers.

In summary, we demonstrated that synthetic phages based on common viral scaffolds can be designed to target a range of different bacterial hosts. Furthermore, we showed that a cocktail containing multiple engineered phages could effectively remove select bacterial targets in mixed microbial populations. We anticipate that the systematic and high-throughput engineering of viral genomes will enable new applications for the editing of microbial communities and enhanced understanding of bacterial viruses. For example, the engineering of common viral scaffolds could help simplify the discovery and manufacturing of novel bacteriophages and reduce the regulatory burden required for the use of phage cocktails as human therapeutics. In future work, we plan to expand our efforts to phages that are not relatives of T3/T7 phages, and phages that target bacteria outside of the Enterobacteriaceae family, including those which are major members of the human gut microbiome (Cryan and Dinan, 2012; Gibson et al., 2014; Zeeuwen et al., 2013). Also, abundant phage sequences contained within metagenomic databases could be synthesized and booted into functional phage particles for study and use. Finally, the systematic deconstruction and manipulation of these viral nanomachines will enable a greater understanding of phage biology and may provide insights that are useful for bio-inspired nanotechnologies.

EXPERIMENTAL PROCEDURES

Strains, Vector, and Primers

Phages T7 (ATCC BAA-1025-B2, NC_001604) and T3 (ATCC 110303-B3, AJ318471) were lab stocks. Phages K1E (NC_007637), K1F (NC_007456), K1-5 (NC_008152), SP6 (NC_004831), and K11 (EU734173) were provided by Ian Molineux (University of Texas, Austin). Phage LUZ19 (NC_010326) was provided by Rob Lavigne (KU Leuven). Phage gh-1 (ATCC 12633-B1, NC_004665) was obtained from ATCC. Synthetic phages are listed in Table

S5. *S. cerevisiae* BY4741 (*MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0*) was obtained from Thermo Scientific. *E. coli* strains BL21 (B, F⁻ *ompT hsdS_B* (*r_B⁻ m_B⁻*) *gal dcm*), DH5α (K-12, F⁻ λ⁻ Φ80d *lacZΔM15 Δ(lacZYA-argF)U169 deoR recA1 endA1 hsdR17* (*r_K⁻ m_K⁻*) *phoA supE44 thi-1 gyrA96 relA1*), BW25113 (K-12, F⁻ λ⁻ Δ(*araD-araB*)567 Δ*lacZ4787::rrmB-3*) *rph-1 Δ(rhaD-rhaB)568 hsdR514*), MG1655 (K-12, F⁻ λ⁻ *ilvG⁻ rfb-50 rph-1*), and Nissle 1917 were obtained from lab stocks. *E. coli* 10G (K-12, F⁻ λ⁻ Δ(*ara leu*) 7697 *araD139 ΔlacX74 galU galK Φ80d lacZΔM15 recA1 endA1 nupG rpsL* (Str^R) Δ(*mrr-hsdRMS-mcrBC*) *tonA*) from Lucigen is an *E. coli* DH10B derivative and is suitable for maintaining large DNA constructs (Durfee et al., 2008). Bacterial strains IJ284 *Klebsiella* sp. 390 (O3:K11), IJ1668 K-12 hybrid; K1 capsule and IJ612 *Salmonella typhimurium* LT2 were provided by Ian Molineux. Virulence-plasmid-less *Y. pseudotuberculosis* IP2666 and YPIII were provided by Joan Mecsas (Tufts University). *P. aeruginosa* PAO1 was obtained from a lab stock. *E. coli* libraries, such as the ECOR group and DECA set, were sourced from the Thomas S. Whittam STEC Center (Michigan State University). *P. putida* C1S (ATCC 23287) was obtained from ATCC. The pRS415 yeast centromere vector with *LEU2* marker (ATCC 87520) was obtained from a lab stock. Primers used in this study are listed in Table S6.

Synthesis of Codon-Optimized 13a Gene 17

The gene was synthesized by Gen9 (Table S2).

Culture Conditions

S. cerevisiae BY4741 was cultured in YPD (1% Bacto Yeast Extract [BD], 2% Bacto Peptone [BD], and 2% dextrose [VWR]) at 30°C. *Y. pseudotuberculosis* strains and *P. putida* C1S were cultured in lysogeny broth (LB) (BD) at 30°C. All other strains were cultured in LB at 37°C.

Preparation of Phage Genomes

Lysates were made by infecting 200 ml of logarithmically growing cells with the appropriate phage at a MOI of 0.1–0.01 and incubating the cultures until clearance. Cells were lysed, and lysates were sterilized by adding 200 μl chloroform (Sigma). Lysates were centrifuged at 8,000 g for 5 min and then filtered through 0.22-μm filters (VWR) to remove cell debris. We added 216 μl of buffer L1 (20 mg/ml RNase A [Sigma], 6 mg/ml DNase I [NEB], 0.2 mg/ml BSA [NEB], 10 mM EDTA [Teknova], 100 mM Tris-HCl [VWR], and 300 mM NaCl [VWR] [pH 7.5]) and incubated everything at 37°C for 1 hr with gentle shaking. Then we added 30 ml of ice-cold buffer L2 [30% polyethylene glycol [PEG] 6000 [Sigma], 3 M NaCl] and stored the samples overnight in 4°C. Samples were centrifuged at 10,000 g for 30 min at 4°C. Phage pellets were suspended in 9 ml buffer L3 (100 mM Tris-HCl, 100 mM NaCl, and 25 mM EDTA [pH 7.5]). Then we added 9 ml buffer L4 [4% SDS (VWR)] and incubated the samples at 70°C for 20 min. After cooling on ice, 9 ml of buffer L5 (2.55 M potassium acetate [pH 4.8] [Teknova]) were added, and the samples were centrifuged at 10,000 g for 30 min at 4°C. Supernatants were passed onto QIAGEN-tip 100 system to extract DNA in accordance with the manufacturer's instructions.

Preparation of PCR Products for Assembling Phage Genomes

All PCR products were prepared with specific primer sets (Table S6) and KAPA HiFi DNA Polymerase. Five to ten 3.8–12.0 kbp PCR products, including the YAC, were used per reaction. Homology arms between the YAC and the phage genomes were added to the first and last phage genome fragments or to the YAC when capturing phage genomes from genomic DNA. The YAC amplicon was gel extracted to reduce background.

Preparation of Yeast Competent Cells

S. cerevisiae BY4741 was grown in 5 ml YPD at 30°C for 24 hr. Overnight cultures were added into 50 ml of YPD, and incubated at 30°C for 4 hr. Cells were harvested by centrifugation at 3,000 g, washed with 25 ml water and then with 1 ml of 100 mM lithium acetate (LiAc) (Alfa Aesar), and suspended in 400 μl of 100 mM LiAc. 50 μl were used for each transformation.

Yeast Transformation

All DNA samples and a linearized pRS415 were collected in a tube (0.5–4.0 μg for each DNA sample and 100 ng linearized pRS415 in 50 μl water), and mixed with the transformation mixture (50 μl yeast competent cell, 240 μl 50% PEG3350 [Sigma], 36 μl 1 M LiAc, 25 μl 2 mg/ml salmon sperm DNA [Sigma]). The mixture

was incubated at 30°C for 30 min, then at 42°C for 20 min or at 42°C for 45 min, centrifuged at 8,000 *g* for 15 s, and suspended in 200 μ l water. Transformants were selected on complete synthetic defined medium without leucine (SD-Leu) (0.67% YNB+Nitrogen [Sunrise Science Products], 0.069% CSM-Leu [Sunrise Science Products], 2% dextrose) agar plates at 30°C for 3 days.

Extraction of Captured Phage Genomes

Individual yeast transformants were picked into SD-Leu liquid medium and incubated at 30°C for 24 hr. DNA was extracted from these cells using the YeaStar Genomic DNA Kit (Zymo Research) or Yeast Genomic DNA Purification Kit (Amresco) in accordance with the manufacturer's instructions.

Rebooting of Phages

An *E. coli* 10G strain was used as a host bacterium for the initial propagation of phages. To reboot T7 and T3 phages, 3 μ l of extracted DNA were electroporated into 20–25 μ l of cells in a 2-mm gap electroporation cuvette (Molecular BioProducts) at 2,500 V, 25 μ F, and 200 Ω using a Gene Pulser Xcell (Bio-Rad). Cells were mixed with 3 ml of LB soft agar (LB + 0.6% agar) warmed at 55°C, poured onto LB plate, and incubated for 4 hr at 37°C. To reboot other phages, after electroporation, cells were incubated at 37°C for 1–2 hr in 1 ml of LB medium. Then we added drops of chloroform to kill the cells and release phages. After centrifugation at 12,000 *g* for 1 min, supernatants were mixed with 300 μ l of overnight cultures of host bacteria for the phages and 3 ml of LB soft agar, poured onto LB plate, and incubated for 4–24 hr at 30°C or 37°C.

One-Time Phage Propagation Assays

We electroporated 10–200 ng of purified phage genomes into *E. coli* 10G. After incubation for 1–2 hr, we added chloroform to kill the cells and release phages that may have failed to lyse cells. Then supernatants were mixed with overnight cultures of each natural host bacteria for each phage in soft agar, poured onto agar plates, incubated for 4–24 hr at 30 to 37°C, and analyzed for plaque formation.

Determination of Plaque-Forming Units

We mixed serially diluted phages in 0.95% saline, 300 μ l of overnight culture of host bacteria, and 3 ml of LB soft agar, and poured the mixture onto LB plates. After 4–24 hr incubation at 30°C or 37°C, phage plaques were counted and PFU/ml values were calculated.

Plaque Formation Assays

We mixed 300 μ l of bacterial overnight cultures and 3 ml of LB soft agar and poured the mixtures onto LB plate. After 5 min at room temperature (RT), 2.5 μ l of 10-fold serially diluted phages in 0.95% saline were spotted onto LB soft agar and incubated at 30°C or 37°C. Efficiency of plating (EOP) was determined with respect to a reference bacterium for each phage. *Klebsiella* sp. 390 was used as the EOP reference for T7_{K11(gp11-12-17)}, K11, and K11_{WT}. *Y. ptb* IP2666 was used for T3_{R(gp17)}. For other phages, BL21 was used as the reference host.

Adsorption Assay

We mixed 100 μ l of $\sim 10^8$ CFU/ml target bacterial strains and phages (MOI = 0.5) and incubated everything at RT for 10 min. Then we added 700 μ l of 0.95% saline and drops of chloroform to kill the cells and prevent the production of progeny phages. After centrifugation at 11,000 *g* for 1 min, supernatants were serially diluted and mixed with 300 μ l of overnight cultures of host bacterial strains and 3 ml of LB soft agar, and the mixtures were poured onto LB plates. After incubation, phage plaques were counted and adsorption efficiencies were calculated according to the following equation:

$$\text{Adsorption efficiency (\%)} = [1 - (\text{PFU of unadsorbed phage} / \text{original PFU in the host bacterium and phage mixture})] \times 100.$$

Bacterial Killing Assays

Overnight cultures of *Y. pseudotuberculosis* IP2666 and *Klebsiella* sp. 390 were diluted 1:200 into LB and grown to log phase ($\sim 10^8$ CFU/ml), i.e., for 5 hr at 30°C and for 3 hr at 37°C, respectively. Bacterial cultures were mixed

with phage lysates (MOI ~ 0.1) and incubated at 30°C or 37°C. At each time point, bacteria were collected, washed twice with 0.95% saline, serially diluted, plated onto LB, and incubated at 30°C or 37°C. Colonies were enumerated to calculate CFU/ml.

Microbial Population Editing Assays

Overnight cultures of *E. coli* Nissle 1917, *Y. pseudotuberculosis* IP2666, and *Klebsiella* sp. 390 or *E. coli* ECOR16 were diluted 1:200 into LB and grown to log phase ($\sim 10^8$ CFU/ml), i.e., for 3 hr at 37°C, for 5 hr at 30°C, for 3 hr at 37°C, and for 3 hr at 37°C, respectively. Cultures were mixed and treated with phage lysates (MOI ~ 0.1) and incubated at 30°C. At each time point, bacteria were collected, washed twice with 0.95% saline, serially diluted, plated onto LB, LB containing 25 μ g/ml carbenicillin (VWR), and LB containing 1 μ g/ml triclosan (VWR), and incubated at 30°C. Colonies were enumerated to calculate CFU/ml.

Statistical Analysis

For all data points in all experiments, three samples were collected. The data are presented as the mean, and the error bars represent the SD. In the subsections "Bacterial Killing Assays" and the "Microbial Population Editing Assays," all CFU data were \log_{10} transformed before analysis. EOPs were \log_{10} transformed before analysis (Figure 3).

SUPPLEMENTAL INFORMATION

Supplemental Information includes six figures and six tables and can be found with this article online at <http://dx.doi.org/10.1016/j.cels.2015.08.013>.

AUTHOR CONTRIBUTIONS

H.A., S.L., and T.K.L. designed the study, wrote the manuscript, and filed a provisional application on this work. H.A., S.L., and D.P.P. performed experiments. All authors analyzed the data and discussed results.

ACKNOWLEDGMENTS

Strains IJ284 *Klebsiella* sp. 390, IJ1668 K-12 hybrid; K1 capsule, IJ612 *S. typhimurium* LT2, K1E, K1F, K1-5, SP6, and K11 were kindly provided by Ian Molineux (University of Texas at Austin). LUZ19 was kindly provided by Rob Lavigne (KU Leuven). *Y. pseudotuberculosis* IP2666 and YPIII were kindly provided by Joan Meccas (Tufts University). We thank Oliver Purcell and Jennifer Henry for critically reading the manuscript. This work was supported by grants from the Defense Threat Reduction Agency (HDTRA1-14-1-0007), the NIH (1DP2OD008435, 1P50GM098792, and 1R01EB017755), and the U.S. Army Research Laboratory/Army Research Office via the Institute for Soldier Nanotechnologies (under contract number W911NF-13-D-0001). H.A. was supported by fellowships from the Japan Society for the Promotion of Science and the Naito Foundation. D.P.P. was supported by the Portuguese Foundation for Science and Technology (SFRH/BD/76440/2011).

Received: April 8, 2015

Revised: July 25, 2015

Accepted: August 28, 2015

Published: September 23, 2015

REFERENCES

- Beier, H., Golomb, M., and Chamberlin, M. (1977). Isolation of recombinants between T7 and T3 bacteriophages and their use in vitro transcriptional mapping. *J. Virol.* 21, 753–765.
- Bessler, W., Freund-Mölbelt, E., Knüfermann, H., Rduolph, C., Thurow, H., and Stirm, S. (1973). A bacteriophage-induced depolymerase active on *Klebsiella* K11 capsular polysaccharide. *Virology* 56, 134–151.
- Bikard, D., Euler, C.W., Jiang, W., Nussenzweig, P.M., Goldberg, G.W., Duportet, X., Fischetti, V.A., and Marraffini, L.A. (2014). Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. *Nat. Biotechnol.* 32, 1146–1150.

- Brüssow, H. (2012). What is needed for phage therapy to become a reality in Western medicine? *Virology* 434, 138–142.
- Carlton, R.M. (1999). Phage therapy: past history and future prospects. *Arch. Immunol. Ther. Exp. (Warsz.)* 47, 267–274.
- Citorik, R.J., Mimee, M., and Lu, T.K. (2014). Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. *Nat. Biotechnol.* 32, 1141–1145.
- Cryan, J.F., and Dinan, T.G. (2012). Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. *Nat. Rev. Neurosci.* 13, 701–712.
- Cuervo, A., Pulido-Cid, M., Chagoyen, M., Arranz, R., González-García, V.A., García-Doval, C., Castón, J.R., Valpuesta, J.M., van Raaij, M.J., Martín-Benito, J., and Carrascosa, J.L. (2013). Structural characterization of the bacteriophage T7 tail machinery. *J. Biol. Chem.* 288, 26290–26299.
- d'Herelle, F. (1931). Bacteriophage as a treatment in acute medical and surgical infections. *Bull. N. Y. Acad. Med.* 7, 329–348.
- Demerec, M., and Fano, U. (1945). Bacteriophage-resistant mutants in *Escherichia coli*. *Genetics* 30, 119–136.
- Dietz, A., Weisser, H.J., Kössel, H., and Hausmann, R. (1990). The gene for *Klebsiella* bacteriophage K11 RNA polymerase: sequence and comparison with the homologous genes of phages T7, T3, and SP6. *Mol. Gen. Genet.* 221, 283–286.
- Dunn, J.J., and Studier, F.W. (1983). Complete nucleotide sequence of bacteriophage T7 DNA and the locations of T7 genetic elements. *J. Mol. Biol.* 166, 477–535.
- Durfee, T., Nelson, R., Baldwin, S., Plunkett, G., 3rd, Burland, V., Mau, B., Petrosino, J.F., Qin, X., Muzny, D.M., Ayele, M., et al. (2008). The complete genome sequence of *Escherichia coli* DH10B: insights into the biology of a laboratory workhorse. *J. Bacteriol.* 190, 2597–2606.
- Fischbach, M.A., and Walsh, C.T. (2009). Antibiotics for emerging pathogens. *Science* 325, 1089–1093.
- García, E., Elliott, J.M., Ramanculov, E., Chain, P.S., Chu, M.C., and Molineux, I.J. (2003). The genome sequence of *Yersinia pestis* bacteriophage phiA1122 reveals an intimate history with the coliphage T3 and T7 genomes. *J. Bacteriol.* 185, 5248–5262.
- Gibson, D.G., Benders, G.A., Andrews-Pfannkoch, C., Denisova, E.A., Baden-Tillson, H., Zaveri, J., Stockwell, T.B., Brownley, A., Thomas, D.W., Algire, M.A., et al. (2008). Complete chemical synthesis, assembly, and cloning of a *Mycoplasma genitalium* genome. *Science* 319, 1215–1220.
- Gibson, M.K., Pesesky, M.W., and Dantas, G. (2014). The yin and yang of bacterial resilience in the human gut microbiota. *J. Mol. Biol.* 426, 3866–3876.
- Grice, E.A., and Segre, J.A. (2012). The human microbiome: our second genome. *Annu. Rev. Genomics Hum. Genet.* 13, 151–170.
- Hendrix, R.W. (2003). Bacteriophage genomics. *Curr. Opin. Microbiol.* 6, 506–511.
- Hu, B., Margolin, W., Molineux, I.J., and Liu, J. (2013). The bacteriophage t7 virion undergoes extensive structural remodeling during infection. *Science* 339, 576–579.
- Jaschke, P.R., Lieberman, E.K., Rodriguez, J., Sierra, A., and Endy, D. (2012). A fully decompressed synthetic bacteriophage ϕ X174 genome assembled and archived in yeast. *Virology* 434, 278–284.
- Kiljunen, S., Datta, N., Dentovskaya, S.V., Anisimov, A.P., Knirel, Y.A., Bengoechea, J.A., Holst, O., and Skurnik, M. (2011). Identification of the lipopolysaccharide core of *Yersinia pestis* and *Yersinia pseudotuberculosis* as the receptor for bacteriophage ϕ A1122. *J. Bacteriol.* 193, 4963–4972.
- Kiro, R., Shitrit, D., and Qimron, U. (2014). Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system. *RNA Biol.* 11, 42–44.
- Lin, A., Jimenez, J., Derr, J., Vera, P., Manapat, M.L., Esvelt, K.M., Villanueva, L., Liu, D.R., and Chen, I.A. (2011). Inhibition of bacterial conjugation by phage M13 and its protein g3p: quantitative analysis and model. *PLoS ONE* 6, e19991.
- Lin, T.Y., Lo, Y.H., Tseng, P.W., Chang, S.F., Lin, Y.T., and Chen, T.S. (2012). A T3 and T7 recombinant phage acquires efficient adsorption and a broader host range. *PLoS ONE* 7, e30954.
- Lu, T.K., and Collins, J.J. (2007). Dispersing biofilms with engineered enzymatic bacteriophage. *Proc. Natl. Acad. Sci. USA* 104, 11197–11202.
- Lu, T.K., and Collins, J.J. (2009). Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. *Proc. Natl. Acad. Sci. USA* 106, 4629–4634.
- Lu, T.K., and Koeris, M.S. (2011). The next generation of bacteriophage therapy. *Curr. Opin. Microbiol.* 14, 524–531.
- Lu, T.K., Koeris, M.S., Chevalier, B.S., Holder, J.W., McKenzie, G.J., and Brownell, D.R. (2013). Recombinant phage and methods. Patent WO 2013049121 A2.
- Martel, B., and Moineau, S. (2014). CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages. *Nucleic Acids Res.* 42, 9504–9513.
- Molineux, I.J. (2006). The T7 group. In *The Bacteriophages*, R. Calendar, ed. (New York: Oxford Univ. Press), pp. 277–301.
- Pajunen, M.I., Elizondo, M.R., Skurnik, M., Kieleczawa, J., and Molineux, I.J. (2002). Complete nucleotide sequence and likely recombinatorial origin of bacteriophage T3. *J. Mol. Biol.* 319, 1115–1132.
- Pouillot, F., Blois, H., and Iris, F. (2010). Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria. *Biosecure Bioterror* 8, 155–169.
- Qimron, U., Tabor, S., and Richardson, C.C. (2010). New details about bacteriophage T7-host interactions. *Microbe*, March 2010. http://www.microbemagazine.org/index.php?option=com_content&view=category&layout=blog&id=376&Itemid=531.
- Rashid, M.H., Revazishvili, T., Dean, T., Butani, A., Verratti, K., Bishop-Lilly, K.A., Sozhamannan, S., Sulakvelidze, A., and Rajanna, C. (2012). A *Yersinia pestis*-specific, lytic phage preparation significantly reduces viable *Y. pestis* on various hard surfaces experimentally contaminated with the bacterium. *Bacteriophage* 2, 168–177.
- Shin, J., Jardine, P., and Noireaux, V. (2012). Genome replication, synthesis, and assembly of the bacteriophage T7 in a single cell-free reaction. *ACS Synth. Biol.* 1, 408–413.
- Steven, A.C., Trus, B.L., Maizel, J.V., Unser, M., Parry, D.A., Wall, J.S., Hainfeld, J.F., and Studier, F.W. (1988). Molecular substructure of a viral receptor-recognition protein. The gp17 tail-fiber of bacteriophage T7. *J. Mol. Biol.* 200, 351–365.
- Sulakvelidze, A., Alavidze, Z., and Morris, J.G., Jr. (2001). Bacteriophage therapy. *Antimicrob. Agents Chemother.* 45, 649–659.
- Tétart, F., Desplats, C., and Krusch, H.M. (1998). Genome plasticity in the distal tail fiber locus of the T-even bacteriophage: recombination between conserved motifs swaps adhesin specificity. *J. Mol. Biol.* 282, 543–556.
- Trojet, S.N., Caumont-Sarcos, A., Perrody, E., Comeau, A.M., and Krusch, H.M. (2011). The gp38 adhesins of the T4 superfamily: a complex modular determinant of the phage's host specificity. *Genome Biol. Evol.* 3, 674–686.
- Yang, S.J., Esvelt, K.M., and Church, G.M. (2014). CRISPR/Cas9-mediated phage resistance is not impeded by the DNA modifications of phage T4. *PLoS ONE* 9, e98811.
- Yoichi, M., Abe, M., Miyayama, K., Unno, H., and Tanji, Y. (2005). Alteration of tail fiber protein gp38 enables T2 phage to infect *Escherichia coli* O157:H7. *J. Biotechnol.* 115, 101–107.
- Zeeuwen, P.L., Kleerebezem, M., Timmerman, H.M., and Schalkwijk, J. (2013). Microbiome and skin diseases. *Curr. Opin. Allergy Clin. Immunol.* 13, 514–520.

Cell Systems

Supplemental Information

Engineering Modular Viral Scaffolds for Targeted Bacterial Population Editing

Hiroki Ando, Sebastien Lemire, Diana P. Pires, and Timothy K. Lu

1 **Supplemental Information**

2

3 **Figure S1. Host ranges of T7 and T3 phages, related to Figure 2. (A)** Host ranges of T7 and
4 T3 phages. Each bacterial overnight culture and LB soft agar were mixed, and poured onto LB
5 plates. 2.5 μ L of 10-fold serially diluted T7 and T3 phages were spotted onto the bacterial lawns
6 and incubated at 37°C. T3 phage did not plaque efficiently on *E. coli* BW25113 and MG1655,
7 whereas T7 phage plaqued efficiently on all tested *E. coli* strains. **(B)** Adsorption assay. Bacteria
8 and T3 phage were mixed at an MOI \sim 0.5 and incubated for 10 min. Growth of adsorbed
9 progeny was stopped by the addition of chloroform. After centrifugation, supernatants were
10 serially diluted and mixed with *E. coli* BL21 and LB soft agar, and poured onto LB plates. After
11 incubation at 37°C, phage plaques were counted, and adsorption efficiencies were calculated.
12 The data are presented as the mean of three independent experiments, and the error bars
13 represent the SD. Small error bars are obscured by bar charts.

14

15 **Figure S2. Plaque formation assays with natural, reconstructed wild-type, and synthetic**
16 **phages, related to Figure 3.** Bacterial lawns were spotted with 2.5 μ L of 10-fold serially diluted
17 phages and incubated at 30 or 37°C. Synthetic phages showed tail-fiber- or tail-component-
18 dependent host ranges and the ability to cross between species. T7 and T7_{WT}, T3 and T3_{WT}, and
19 K11 and K11_{WT} phages are the same at the genetic level; however, T7_{WT}, T3_{WT}, and K11_{WT}
20 phages were created by capturing the genomes in yeast and then rebooting these phage genomes
21 in bacteria. Efficiency of plating (EOP) results are shown in Figure 3.

22

23 **Figure S3. Plaque formation assays with T7_{K11(gp11-12-17)} and K11_{T7(gp11-12-17)}, related to**
24 **Figure 5.** 2.5 µL of 10-fold serially diluted phages were spotted onto bacterial lawns and
25 incubated at 37°C. K11_{T7(gp11-12-17)} adopted the host range of T7_{WT} while T7_{K11(gp11-12-17)} adopted
26 the host range of K11, thus demonstrating that tail component swapping can lead to acquisition
27 of novel host ranges.

28

29 **Figure S4. Antimicrobial susceptibilities of *E. coli* Nissle 1917, *Klebsiella* sp. 390, and *Y.***
30 ***pseudotuberculosis* IP2666, related to Figure 6. (A)** Five microliters of each overnight cultures
31 (>10⁹ CFU/ml) for each bacteria were streaked on LB plates with or without antibiotics. Plates
32 were incubated at 30°C for 24 h. *Klebsiella* sp. 390 was naturally resistant to 25 µg/ml
33 carbenicillin and *Y. ptb* IP2666 was naturally resistant to 1 µg/ml triclosan, while *E. coli* Nissle
34 1917 was sensitive to both. **(B)** Diluted log-phase cultures were plated onto LB with or without
35 antibiotics. After incubation at 30°C for 18-24 h, colonies were enumerated. These
36 concentrations of antimicrobials completely killed susceptible strains but did not visibly affect
37 the growth of resistant strains.

38

39 **Figure S5. Antimicrobial susceptibilities of *E. coli* Nissle 1917, *E. coli* ECOR16, and *Y.***
40 ***pseudotuberculosis* IP2666, related to Figure S6. (A)** Five microliters of each overnight
41 cultures (>10⁹ CFU/ml) for each bacteria were streaked on LB plates with or without antibiotics.
42 Plates were incubated at 30°C for 24 h. *E. coli* ECOR16 was naturally resistant to 50 µg/ml
43 streptomycin and *Y. ptb* IP2666 was naturally resistant to 1 µg/ml triclosan, while *E. coli* Nissle
44 1917 was sensitive to both. **(B)** Diluted log-phase cultures were plated onto LB with or without
45 antibiotics. After incubation at 30°C for 18-24 h, colonies were enumerated.

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66

Figure S6. Microbial population editing assay with synthetic T3-based cocktail, related to

Figure 6. A synthetic microbial community composed of *E. coli* Nissle 1917, *E. coli* ECOR16, and *Y. ptb* IP2666 was treated with individual synthetic phages (T3_{WT} and T3_{R(gp17)}) and the pairwise combination of these phages. After adding ~10⁷ PFU/ml of each phage, the resulting samples were incubated at 30°C with shaking for 1 h. At each time point, bacteria were collected, washed in saline, serially diluted, and plated onto selective plates for viable cell counts after a 24 h incubation at 30°C. The data are presented as the mean of three independent experiments and the total numbers of cells (CFU/ml) are shown. The sizes of the pie charts reflect the total number of cells. Note that the chart does not allow the display of fractions smaller than ~1%. The detailed data are shown in Table S4B.

Table S1, related to Figure 1. Results of plaque formation assays on *E. cloni* 10G and one-time phage propagation assays in *E. cloni* 10G for natural phages.

Table S2, related to Figure 2. Sequence of codon-optimized and fully synthesized gene 17 of phage 13a.

Table S3, related to Figure 4 and 5. (A) Detailed data for the *Y. ptb* IP2666 killing assay (Figure 4C). (B) Detailed data for the *Klebsiella* sp. 390 killing assay (Figure 5C).

67 **Table S4, related to Figure 6 and S6.** (A) Detailed data for microbial population editing with
68 engineered phages from Figure 6. (B) Detailed data for microbial population editing with
69 engineered phages from Figure S6.

70

71 **Table S5, related to Experimental Procedures.** Description of synthetic phages created in this
72 study.

73

74 **Table S6, related to Experimental Procedures.** Oligonucleotide primers used in this study.

Figure S1





Figure S4

A



Control
LB

Carbenicillin
25 μ g/ml

Triclosan
1 μ g/ml



B

E. coli Nissle 1917



Klebsiella sp. 390




Y. ptb IP2666



Figure S5

A



Control
LB

Streptomycin
50 μ g/ml

Triclosan
1 μ g/ml



B

E. coli Nissle 1917



E. coli ECOR16



Y. ptb IP2666



Figure S6




Table S1

One-time phage propagation assay.

Phage	Plaque formation on <i>E. cloni</i> 10G	Propagation in <i>E. cloni</i> 10G	Host bacteria
T7	Yes	Yes	<i>E. coli</i> BL21
T3	Yes	Yes	<i>E. coli</i> BL21
K1E	No	Yes	<i>E. coli</i> IJ1668
K1F	No	Yes	<i>E. coli</i> IJ1668
K1-5	No	Yes	<i>E. coli</i> IJ1668
SP6	No	Yes	<i>S. typhimurium</i> IJ612
LUZ19	No	Yes	<i>P. aeruginosa</i> PAO1
gh-1	No	Yes	<i>P. putida</i> C1S
K11	No	Yes	<i>Klebsiella</i> sp. 390

Table S2

Sequence of codon-optimized 13a gene 17.

ATGGCGAATGTGATTAAGACCGTTCTGACGTATCAGTTAGATGGATCCAATAGCGATTTTAATATTCCATTTGAAT
ACCTGGCGCGCAAATTTGTCGCCGTGACGCTGATTGGGGTTGATCGCAAGGTATTAACCATTAACACCGACTAT
CGCTTTGCTACGCGCACGACCATCTCTCTCACTAAGGCGTGGGGACCGGCGGATGGTTATACTACCATCGAGT
TGCGCCGCGTTACGTGACAACCTGACCGCCTCGTGGACTTTACCGACGGTAGCATTCTGCGTGCGTACGATC
TTAACGTGGCCCAGATTGAGACAATCCACGTGCGAGAAGAAGCACGTGACCTGACTGCCGACACCATTGGCG
TAAACAATGACGGCCATCTGGATGCGCGCGGTGCGCCGATTGTCAATTTGGCGAACGCCGTTGATGATCGTGA
TGCGGTGCCGCTCGGCCAACTCAAACTATGAATCAGAACAGTTGGCAGGCTCGCAACGAGGCACTGCAATT
CCGCAATGAAGCCGAAACTTTTCGCAATCAGGCGGAAGGTTTTAAAACGAGAGCGGTACTAACGCCACTAAC
ACGAAACAGTGGCGCGACGAGACAAAAGGCTTCCGCGACGAAGCGGAACAATTTAAGAACACCGCGGGTCA
GTATGATACATCCGCGGGTAACAGCGCGAGCGCTGCCCATCAGAGCGAAGTAAACGCAGAAAACAGTGCGAC
CGCGTCCGCTAATAGCGCCACCTCGCCGAGCAACAGGCCGATCGCGCGGAGCGTGAAGCTGATAAACTCG
GCAACTTTAATGGTCTTGCTGGTGGATCGACAAGGTCGACGGCACAACCGTGTATTGGAAAGGTAACATCCA
TGCAAACGGTCGCCTCTACATCACGACCAATGGCTTCGACTGCGGTCAATATCAGCAGTTCTTTGGTGGCGAT
ACGAATCGCTACAGCGTGATGGAATGGGGTGACGATAACGGGTGGCTGATGTATGTGCAGCGCCGTGAATGG
ACCACCGCAATCGGCGGCAACATTCAGTTGGTTGTCAACGGTCAGATCATCACCCAGGGCGGTGCCATGACG
GGGCAACTGAACTTCAGAATGGTCACGTTCTGCAATTGGAATCCGCCAGTGACAAAGCGCATTATATTTATC
AAAGGATGGCAACCGTAATAATTGGTATATTGGTCGTGGATCGGATAACAATAACGACTGCACGTTTCACTCCTA
CGTTCACGGTACCACGTTAACCTTGAAACAGGATTATGCAGTGGTCAACAAACACTTTCATGTGGGACAGGCG
GTCGTGTCAACTGATGGCAATATCCAGGGCACCAATGGGGTGGTAAATGGCTGGATGTTTATTTAAATGATAC
ATACGTTAAGAAAACGATGGCTTGGACACAAGTGTGGGCTGCGGACTCGGGTAAATACCTCCCGGGTGGGAG
TCAAACCTGATACTCTGCCGACGATCTGCGTTTCCGCAACATCTGGATTTCGTACGCGTAACAACCTATTGGAAC
TTTTTCGCACGGGCCCGGATGGGATCTATTTCTGTGCGGCTGAAGGAGGTTGGCTGAAATTTAGATCCACTC
AAACGGTCGCGTCTTCAAAAACATCTCTGATCGCGACGCACCCCGACCGCAATCGCTGTGGAAGACGTTTAA

Table S3

A

Time after treatment	log ₁₀ (mean ± SD CFU/ml)		
	Control (no phage)	T3 _{WT}	T3 _{R(gp17)}
0 min	8.312 ± 0.052	8.312 ± 0.052	8.312 ± 0.052
30 min	8.503 ± 0.131	8.412 ± 0.055	7.799 ± 0.048
60 min	8.585 ± 0.046	8.556 ± 0.020	6.369 ± 0.096
90 min	8.732 ± 0.072	8.685 ± 0.046	3.301 ± 0
120 min	8.727 ± 0.116	8.767 ± 0.120	3.301 ± 0
150 min	9.016 ± 0.100	8.903 ± 0.246	3.301 ± 0
180 min	9.219 ± 0.051	9.263 ± 0.084	3.301 ± 0

B

Time after treatment	log ₁₀ (mean ± SD CFU/ml)			
	Control (no phage)	K11 _{WT}	T7 _{WT}	T7 _{K11(gp11-12-17)}
0 min	8.579 ± 0.019	8.579 ± 0.019	8.579 ± 0.019	8.579 ± 0.019
15 min	8.796 ± 0.070	7.560 ± 0.197	8.715 ± 0.035	7.952 ± 0.269
30 min	8.869 ± 0.188	5.400 ± 0.288	8.900 ± 0.142	6.354 ± 0.195
45 min	9.117 ± 0.086	3.301 ± 0	9.053 ± 0.037	5.053 ± 0.518
60 min	9.199 ± 0.145	3.301 ± 0	9.253 ± 0.127	5.036 ± 0.419
75 min	9.365 ± 0.048	3.301 ± 0	9.350 ± 0.069	5.026 ± 0.037

Table S4

A

Treatment	Time after treatment	<i>E. coli</i> Nissle 1917	log ₁₀ (mean ± SD CFU/ml)	
			<i>Klebsiella</i> sp. 390	<i>Y. ptb</i> IP2666
No phage	0 min	8.300 ± 0.036	8.307 ± 0.086	8.290 ± 0.155
	30 min	8.327 ± 0.037	8.407 ± 0.084	8.312 ± 0.125
	60 min	8.598 ± 0.148	8.761 ± 0.123	8.524 ± 0.180
T7 _{WT}	30 min	8.355 ± 0.018	8.390 ± 0.043	6.341 ± 0.032
	60 min	8.768 ± 0.114	8.560 ± 0.400	3.301 ± 0
T3 _{WT}	30 min	8.327 ± 0.037	8.379 ± 0.030	8.331 ± 0.100
	60 min	8.861 ± 0.059	8.935 ± 0.046	8.709 ± 0.192
K11 _{WT}	30 min	8.368 ± 0.018	5.386 ± 0.154	8.327 ± 0.037
	60 min	8.935 ± 0.046	3.301 ± 0	8.820 ± 0.059
T7 _{K11gp(11-12-17)}	30 min	8.379 ± 0.030	6.740 ± 0.230	8.361 ± 0.080
	60 min	8.861 ± 0.059	5.560 ± 0.197	8.324 ± 0.643
T3 _{R(gp17)}	30 min	8.367 ± 0.034	8.436 ± 0.015	7.587 ± 0.163
	60 min	8.984 ± 0.115	8.994 ± 0.072	6.327 ± 0.460
T7 and T7 _{K11(gp11-12-17)}	30 min	8.414 ± 0.027	6.968 ± 0.046	6.588 ± 0.223
	60 min	8.987 ± 0.063	5.683 ± 0.350	3.301 ± 0

B

Treatment	Time after treatment	<i>E. coli</i> Nissle 1917	log ₁₀ (mean ± SD CFU/ml)	
			<i>E. coli</i> ECOR16	<i>Y. ptb</i> IP2666
No phage	0 min	8.127 ± 0.127	8.354 ± 0.037	8.295 ± 0.072
	30 min	8.183 ± 0.346	8.339 ± 0.059	8.326 ± 0.059
	60 min	8.657 ± 0.177	8.793 ± 0.084	8.529 ± 0.187
T3 _{WT}	30 min	8.422 ± 0.131	7.249 ± 0.073	8.195 ± 0.155
	60 min	8.574 ± 0.354	5.534 ± 0.111	8.545 ± 0.169
T3 _{R(gp17)}	30 min	8.604 ± 0.031	8.379 ± 0.030	7.355 ± 0.153
	60 min	8.917 ± 0.203	8.486 ± 0.209	6.869 ± 0.630
T3 _{WT} and T3 _{R(gp17)}	30 min	8.219 ± 0.622	7.008 ± 0.500	7.271 ± 0.022
	60 min	9.106 ± 0.138	4.271 ± 0.022	6.781 ± 0.098

Table S5

Synthetic phages.

Phage	Genotype	Description
T7 _{WT}	T7 wild-type	Synthesized from PCR products
T3 _{WT}	T3 wild-type	Synthesized from PCR products
K1E _{WT}	K1E wild-type	Synthesized from PCR products
K1F _{WT}	K1F wild-type	Synthesized from PCR products
K1-5 _{WT}	K1-5 wild-type	Synthesized from PCR products
SP6 _{WT}	SP6 wild-type	Synthesized from PCR products
gh-1 _{WT}	gh-1 wild-type	Synthesized from PCR products
K11 _{WT}	K11 wild-type	Synthesized from PCR products
T7 _{T3(C-gp17)}	T7 _{WT} gene 17 (1-447)-T3 gene 17 (448-1677)	T7 with T7-T3 hybrid tail fiber
T7 _{T3(gp17)}	T7 _{WT} Δgene 17, T3 gene 17	T7 with T3 tail fiber
T7 _{13a(C-gp17)}	T7 _{WT} gene 17 (1-450)-13a gene 17 (451-1677)	T7 with T7-13a hybrid tail fiber
T7 _{13a(gp17)}	T7 _{WT} Δgene 17, 13a gene 17	T7 with 13a tail fiber
T7 _{K11(gp11-12-17)}	T7 _{WT} Δgene (11 12 17), K11 gene (11 12 17)	T7 with K11 tail
T3 _{T7(C-gp17)}	T3 _{WT} gene 17(1-447)-T7 gene 17(448-1662)	T3 with T3-T7 hybrid tail fiber
T3 _{T7(gp17)}	T3 _{WT} Δgene 17, T7 gene 17	T3 with T7 tail fiber
T3 _{R(gp17)}	T3 _{WT} Δgene 17, R gene 17	T3 with R tail fiber
K11 _{T7(gp11-12-17)}	K11 _{WT} Δgene (11 12 17), T7 gene (11-12 17)	K11 with T7 tail